SH-217 is a novel small molecule in our development at present. This new compound targets the NLRP3 inflammasome. Its mechanism of action specifically involved: (1) blocking the priming of the NLRP3 inflammasome; (2) inhibition of ASC oligomerisation and NLRP3 inflammasome assembly and (3) activation of autophagy. According to the mode of action, SH-217 can be used to solve the problem like “long Covid”.
We also focus on the medicine development for irreversible diseases and unmet medical needs, SH-217 is one of those.
SANBIOZI 